CD19-CAR-T细胞治疗淋巴细胞白血病

Treatment of lymphoblastic leukemia with CD19-specific modified chimeric antigen receptor T cells

Bioengineered T cells, which are the genetically manipulated T cells to express chimeric antigen receptor T Cell (CAR T) against leukemia-associated specific antigens, were applied to treat acute and chronic lymphocytic leukemia with CAR T. CAR T cells combined with cell-surface binding site and anti-CD19 chimeric antigen receptor can treat diseases through T cells transfection. CAR T cells can recognize the CD19 antigen on B cells with specific cell-surface loci. CAR T cells can proliferate by 1000 times and differentiate in vivo by the CD19 antigen stimulation, therefore, kill the acute and chronic lymphocytic leukemia cells effectively. This article briefly reviews the CAR T cells and the effect of CAR T cells on acute and chronic lymphoblastic leukemia.


CD19-CAR-T细胞治疗淋巴细胞白血病

基因工程T细胞，即操纵基因使得T细胞表达嵌合抗原受体的T细胞（CAR-T）对抗白血病相关抗原，用于治疗急性和慢性淋巴细胞白血病。CAR-T细胞利用细胞表面结合域和CD19嵌合抗原受体结合来对抗相关的疾病。CAR-T细胞可以与细胞表面特异性位点识别B细胞上的CD19抗原。在体内通过CD19抗原的刺激，CAR-T细胞可以增殖1000倍，因此，对于急性和慢性淋巴细胞性白血病细胞有效。本文简要回顾了CAR-T细胞和细其对急性和慢性淋巴细胞白血病的作用。
出自爱康得生物技术